Seegene to Present at the 32nd Annual J.P. Morgan Healthcare Conference
GAITHERSBURG, MD and SEOUL, KOREA--(Marketwired - Dec 19, 2013) - Seegene Inc., (KOSDAQ: 096530), a leading developer of multiplexed molecular technologies and diagnostic tests, today announced that it will present at the 32nd annual J.P. Morgan Healthcare Conference. Seegene's Founder and CEO, Dr. Jong-Yoon Chun, will review the company's financial performance, growth strategy, molecular innovations, and strategic push into companion diagnostics.
Dr. Chun will be presenting on Tuesday, January 14, 2014 at 3:30pm in the Victor's Room (32nd Floor) at the Westin St. Francis Hotel in San Francisco. The conference will take place Monday, January 13, through Thursday, January 16, 2014.
"We look forward to present how Seegene continues to push the boundaries of technological innovation in the areas of amplification and detection of nucleic acids. Our goal is to develop molecular tests and molecular diagnostic tests that empower cost-effective, responsive and tailored patient care in the clinic. Using our highly multiplexed diagnostic tests, clinicians can gain accurate and actionable information about a patient's symptoms within hours utilizing a wide array of sample types," said Dr. Chun.
The annual J.P. Morgan Healthcare Conference is the largest healthcare investment symposium in the industry. The expected attendance includes more than 300 companies, both public and private, to deliver presentations to more than 3,000 investors.
Seegene is the world's leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene's core enabling technologies -- ACP™, DPO™, READ, and TOCE™ -- are the foundation for M-MoDx tests that can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. Seegene's products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene's mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.